Several other equities research analysts have also commented on the company. Cowen restated a buy rating on shares of Molecular Templates in a research report on Wednesday, November 13th. Zacks Investment Research downgraded Molecular Templates from a buy rating to a hold rating in a research note on Tuesday, February 11th. Finally, ValuEngine downgraded Molecular Templates from a sell rating to a strong sell rating in a research note on Friday, January 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $14.00.
Shares of NASDAQ MTEM opened at $17.83 on Thursday. The stock has a market capitalization of $658.96 million, a PE ratio of -10.94 and a beta of 3.33. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.66 and a quick ratio of 2.66. The business has a fifty day moving average price of $14.47 and a two-hundred day moving average price of $9.77. Molecular Templates has a fifty-two week low of $4.51 and a fifty-two week high of $18.38.
About Molecular Templates
Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma.
Recommended Story: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.